Tango Therapeutics (NASDAQ:TNGX) Stock Gets Price Target Trim from HC Wainwright

Tango Therapeutics (NASDAQ:TNGX) had its price target decreased by HC Wainwright from $68.00 to $67.00 in a report released on Tuesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Tango Therapeutics’ Q4 2026 earnings at ($0.41) EPS, FY2026 earnings at ($1.50) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.44) EPS, Q4 2027 earnings at ($0.46) EPS and FY2027 earnings at ($1.75) EPS.

TNGX has been the topic of several other reports. Guggenheim increased their price objective on shares of Tango Therapeutics from $32.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. William Blair initiated coverage on shares of Tango Therapeutics in a research note on Friday, October 16th. They set an “outperform” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Tango Therapeutics in a research note on Wednesday, November 4th. Wall Street Zen downgraded shares of Tango Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Finally, Zacks Research lowered shares of Tango Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 27th. Thirteen analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $45.54.

Tango Therapeutics Trading Down 3.4%

Shares of NASDAQ:TNGX opened at $24.85 on Tuesday. Tango Therapeutics has a 1 year low of $7.49 and a 1 year high of $34.39. The business’s 50 day moving average price is $23.47 and its 200-day moving average price is $22.72.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). Research analysts predict that Tango Therapeutics will post -1.46 EPS for the current year.

Insider Buying and Selling

In related news, insider Adam Crystal sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $22.42, for a total transaction of $112,100.00. Following the completion of the sale, the insider directly owned 115,743 shares in the company, valued at approximately $2,594,958.06. The trade was a 4.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jessica Newcomb sold 7,031 shares of the stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $22.42, for a total value of $157,635.02. Following the completion of the transaction, the insider directly owned 52,090 shares of the company’s stock, valued at approximately $1,167,857.80. This represents a 11.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 47,231 shares of company stock worth $1,129,029 over the last ninety days. Corporate insiders own 6.50% of the company’s stock.

Institutional Investors Weigh In On Tango Therapeutics

A number of large investors have recently modified their holdings of the business. Allspring Global Investments Holdings LLC raised its position in shares of Tango Therapeutics by 4.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 13,734 shares of the company’s stock valued at $336,000 after buying an additional 534 shares during the last quarter. Allworth Financial LP boosted its position in Tango Therapeutics by 100.9% during the second quarter. Allworth Financial LP now owns 1,131 shares of the company’s stock worth $35,000 after acquiring an additional 568 shares during the last quarter. Nykredit A S acquired a new position in Tango Therapeutics during the second quarter worth about $26,000. Dimensional Fund Advisors LP boosted its position in Tango Therapeutics by 0.5% during the first quarter. Dimensional Fund Advisors LP now owns 489,348 shares of the company’s stock worth $10,237,000 after acquiring an additional 2,272 shares during the last quarter. Finally, Global Retirement Partners LLC purchased a new stake in Tango Therapeutics during the 2nd quarter valued at about $122,000. Hedge funds and other institutional investors own 78.99% of the company’s stock.

Key Tango Therapeutics News

Here’s some of the latest news about TNGX:

• Positive Sentiment: Canaccord Genuity maintained its Buy rating on TNGX, while JPMorgan also issued a positive outlook. Separate coverage linked an analyst upgrade to a recent share-price rally. Canaccord Genuity rating JPMorgan outlook Analyst upgrade and rally
• Negative Sentiment: HC Wainwright lowered its 2026 and 2027 EPS forecasts, including its FY2027 estimate from a loss of $1.54 to $1.75 per share. It nevertheless kept its Buy rating and $67 target. The revised forecasts point to greater expected losses and could weigh on sentiment. HC Wainwright forecast changes
• Negative Sentiment: Wedbush cut its price target, adding a less-bullish analyst signal. Separately, Tango’s reported quarterly loss per share was wider than analysts expected. Wedbush target cut

About Tango Therapeutics

Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.